Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Feb 18;14:1255–1268. doi: 10.2147/IJN.S191858

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Tan et al. This work is published and licensed by Dove Medical Press Limited

The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

In vivo antitumor efficacy of the different formulations in H22 tumor-bearing BALB/c female mice.

Notes: (A) Tumor volume and (B) body weight changes during the treatment period. The black arrows on the x-axis represent the time points of intravenous injections (ie, Days 1, 3, 5, 8, and 11). The injected dose of Dox and siBcl-2 per administration was 5 mg/kg and 1.2 mg/kg, respectively (n=5). (C) The weight and (D) image of tumors separated from the mice at the end of the experiment. (E) H&E staining of the heart and tumor tissues, and immunofluorescence analysis of the tumor tissues. The red dotted circles represent damaged cardiomyocytes after free Dox treatment. Data are presented as mean ± SD (n=5). *P<0.05 and **P<0.01.

Abbreviations: Dox, doxorubicin; LPs, liposomes; siBcl-2, Bcl-2 siRNA; TPGS, D-α-tocopherol polyethylene glycol 1000 succinate.

In vivo antitumor efficacy of the different formulations in H22 tumor-bearing BALB/c female mice.

Notes: (A) Tumor volume and (B) body weight changes during the treatment period. The black arrows on the x-axis represent the time points of intravenous injections (ie, Days 1, 3, 5, 8, and 11). The injected dose of Dox and siBcl-2 per administration was 5 mg/kg and 1.2 mg/kg, respectively (n=5). (C) The weight and (D) image of tumors separated from the mice at the end of the experiment. (E) H&E staining of the heart and tumor tissues, and immunofluorescence analysis of the tumor tissues. The red dotted circles represent damaged cardiomyocytes after free Dox treatment. Data are presented as mean ± SD (n=5). *P<0.05 and **P<0.01.

Abbreviations: Dox, doxorubicin; LPs, liposomes; siBcl-2, Bcl-2 siRNA; TPGS, D-α-tocopherol polyethylene glycol 1000 succinate.